A Phase I Trial of Intratumoral Administration of CCL21-gene Modified Dendritic Cell (DC) Combined With Intravenous Pembrolizumab for Advanced NSCLC

Investigator(s):

Steven M. Dubinett, M.D.;

Organization: 

UCLA

NCT Number: 

NCT03546361

Disease Name: 

Lung Cancer

Disease Category: 

Cancer

Trial Phases: 

Phase 1

Trial Status: 

Recruiting

Trial Contact: 

Lia Etheridge 
(310) 825-7174 
letheridge@mednet.ucla.edu